Researchers use salmonella to deliver oral DNA vaccines; Inviragen and the International Vaccine Institute strengthen partnership;

 @AlisonBFierce: The percentage of drug-resistant malaria cases is on the rise in Southeast Asia, a cause for concern among experts. More | Follow @AlisonBFierce

> Researchers use self-destructing salmonella to deliver oral DNA vaccines. Story

> Astellas Pharma launched in Japan the Quattrovac subcutaneous injection syringe, which delivers a combined vaccine for the prevention of pertussis, diphtheria, tetanus and poliomyelitis. Story

> The Sabin Vaccine Institute started Part II of its Phase I clinical trial of its Na-GST-1 vaccine candidate, a human hookworm vaccine. Release

> Immatics' renal cancer vaccine IMA901 completed Phase III patient recruitment and was granted U.S. orphan drug designation by the FDA. Release

And Finally... Inviragen and the International Vaccine Institute announced a collaboration to assess the total health burden of dengue cases in Colombia and Thailand. Report

Suggested Articles

As a new coronavirus spreads, vaccine researchers have started work on candidates against the virus—and one could enter the clinic in a few months.

Merck's HPV vaccine Gardasil is delivering blockbuster sales as demand surges. But high demand has caused somewhat of a supply constraint.

GSK's Shingrix has generated blockbuster sales early in the launch, but there's a lot of remaining opportunity, an exec said at JPM.